CRISPR Therapeutics (CRSP):
The last month has certainly been exciting in the world of CRISPR-Cas9. There were some incredible studies that were able to show that the technology was able to completely cure mice that had HIV/AIDS by using genetic editing techniques.
The next study will apply CRISPR to possibly cure HIV/AIDS in primates.
Another study was able to show the successful “knockout” of a genetic mutation in both mice and monkeys using CRISPR.
To be balanced, there was a negative study that came out showing some off-target mutations by a group that was working with CRISPR-Cas9, but the scientific community was quick to jump in and put the testing in context. There is a lot of experimentation going on right now with CRISPR, and the use of this powerful technology is becoming more and more political.
But the agricultural developments are nothing short of extraordinary. Another study showed the
improvement of tomato plants with 100% accuracy rates, with no off-target mutations.
Shares of CRISPR Therapeutics traded down 14.6% this month on the back of the negative report mentioned earlier.
While CRISPR Therapeutics has not publicly addressed this report, Intellia Therapeutics did. Intellia suggested the report was highly flawed and lacking in hard proof. This has been broadly supported by the industry.
CRISPR Therapeutics will also be presenting at the European Hematology Association in June. The presentation will highlight their research on sickle cell disease and their pogre toward a product ready for clinical trials.
CRISPR Therapeutics (CRSP) remains a strong buy up to $17.
Intellia Therapeutics (NTLA)
Intellia’s stock also sold off sharply trinc the negative report. Unlike its sister company, Intellia elected to address the report:
“The claim contradicts the well-established mechanism of CRISPR action, as described in scores of publications on CRISPR/Cas9,” Intellia said. “We have previously reported that we are able to find therapeutically relevant guides with no detectable off-target editing, which we are continuing to advance to the clinic to bring genome editing treatments to thousands of patients.” According to Intellia, the authors failed to present
evidence to back up their claim that the genetic differences in the mice were caused by CRISPR/Cas9 while overlooking alternative explanations.
NTLA is down 12.7% for the month.
NTLA remains a strong buy up to $15.
•
Editas Medicine (EDIT):
Shares of Editas were affected as well during the last few weeks:
"Creating safe and effective CRISPR medicines is our goal," Editas said in a statement. "Part of how we do that is to rigorously assess the specificity of our molecules. We’ve published extensively on our approach to specificity and have demonstrated that we can make CRISPR molecules with no detectable off-target effects.”
EDIT is down 17% for the month. As per my earlier comments, pullbacks like these present incredible buying opportunities for our CRISPR-Cas9-related stocks. If you have not established a basket of these three companies yet, this is a perfect time to do so.
Editas Medicine (EDIT) remains a strong buy up to $20.
En resumen:
- Se ha publicado un informe que denuncia efectos secundarias en la tecnología.
- CRISPR no notificó el informe, si lo hicieron Editas e Intellia.
- La "comunidad científica" tiene dudas sobre dicho informe.
- La precisión en la mejora de tomates ha sido del 100%
- En junio CRISPR presentará en Europa sus avances en tratamiento celular.
- La tecnología se ha convertido en un asunto político y es por ello el fomento del informe contradictorio.
Recomendación del editor
compra de las tres a 17, 15 y 20
